{"id":"W2398570616","doi":"10.1158/1078-0432.ccr-16-0506","title":"A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":165,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Drug Research and Development","funders":"Cancer Research UK","keywords":"Glioblastoma; Temozolomide; Immunogenicity; Medicine; Adjuvant; Cancer; Oncology; Clinical trial; Chemoradiotherapy; Internal medicine; Antigen; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001263801,0.001098528,0.001648085,0.0002132644,0.0003258195,0.0006855378,0.0005305255,0.0008109864,0.002449155],"category_scores_gemma":[0.0007602333,0.0004413484,0.0007948978,0.0002171644,0.000638613,0.0006423558,0.000350733,0.002206197,0.0006877607],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00084003,"about_ca_system_score_gemma":0.00147637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009918611,"about_ca_topic_score_gemma":0.00248735,"domain_scores_codex":[0.9995368,0.0002144215,0.00002480263,0.00008116717,0.00003885099,0.0001040284],"domain_scores_gemma":[0.9993469,0.00005976986,0.0001193148,0.00006166281,0.00004514041,0.0003671568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7422111,0.0497866,0.01700243,0.0008009276,0.001446149,0.0005890781,0.0004223151,0.001794894,0.06240368,0.0002645871,0.004952988,0.1183252],"study_design_scores_gemma":[0.3407639,0.6309426,0.0195989,0.00003341107,0.0003561735,0.0003058408,0.00006550393,0.0006901733,0.003858125,0.0001109998,0.003249267,0.00002503491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955494,0.001293905,0.0002816004,0.000296896,0.0001320318,0.001320969,0.0004211836,0.0000396219,0.0006642729],"genre_scores_gemma":[0.9931103,0.0008757386,0.0007554524,0.0008380046,0.0001410326,0.001447685,0.001164703,0.0000147242,0.00165246],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002449155,"threshold_uncertainty_score":0.008193254,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1092635865907657,"score_gpt":0.4676425387001081,"score_spread":0.3583789521093425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}